학술논문
PMD22 - The Budget Impact Of Introducing A PD-L1 Assay To Select Patients With Metastatic Nsclc Who Are Potential Candidates For Treatment With Immune Checkpoint Inhibitors
Document Type
Abstract
Author
Source
In Value in Health October-November 2017 20(9):A576-A576
Subject
Language
ISSN
1098-3015